188 related articles for article (PubMed ID: 15292270)
21. Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells.
Rakhshan F; Day TA; Blakely RD; Barker EL
J Pharmacol Exp Ther; 2000 Mar; 292(3):960-7. PubMed ID: 10688610
[TBL] [Abstract][Full Text] [Related]
22. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase.
Bisogno T; Melck D; De Petrocellis L; Bobrov MYu ; Gretskaya NM; Bezuglov VV; Sitachitta N; Gerwick WH; Di Marzo V
Biochem Biophys Res Commun; 1998 Jul; 248(3):515-22. PubMed ID: 9703957
[TBL] [Abstract][Full Text] [Related]
23. Lipid droplets are novel sites of N-acylethanolamine inactivation by fatty acid amide hydrolase-2.
Kaczocha M; Glaser ST; Chae J; Brown DA; Deutsch DG
J Biol Chem; 2010 Jan; 285(4):2796-806. PubMed ID: 19926788
[TBL] [Abstract][Full Text] [Related]
24. Conformational requirements for endocannabinoid interaction with the cannabinoid receptors, the anandamide transporter and fatty acid amidohydrolase.
Reggio PH; Traore H
Chem Phys Lipids; 2000 Nov; 108(1-2):15-35. PubMed ID: 11106780
[TBL] [Abstract][Full Text] [Related]
25. Anandamide uptake is consistent with rate-limited diffusion and is regulated by the degree of its hydrolysis by fatty acid amide hydrolase.
Kaczocha M; Hermann A; Glaser ST; Bojesen IN; Deutsch DG
J Biol Chem; 2006 Apr; 281(14):9066-75. PubMed ID: 16461355
[TBL] [Abstract][Full Text] [Related]
26. Novel selective and metabolically stable inhibitors of anandamide cellular uptake.
Ortar G; Ligresti A; De Petrocellis L; Morera E; Di Marzo V
Biochem Pharmacol; 2003 May; 65(9):1473-81. PubMed ID: 12732359
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as an FAAH substrate.
Vandevoorde S; Fowler CJ
Br J Pharmacol; 2005 Aug; 145(7):885-93. PubMed ID: 15895107
[TBL] [Abstract][Full Text] [Related]
28. Identification of intracellular carriers for the endocannabinoid anandamide.
Kaczocha M; Glaser ST; Deutsch DG
Proc Natl Acad Sci U S A; 2009 Apr; 106(15):6375-80. PubMed ID: 19307565
[TBL] [Abstract][Full Text] [Related]
29. Anandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6.
Sridar C; Snider NT; Hollenberg PF
Drug Metab Dispos; 2011 May; 39(5):782-8. PubMed ID: 21289075
[TBL] [Abstract][Full Text] [Related]
30. Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes.
Maccarrone M; De Petrocellis L; Bari M; Fezza F; Salvati S; Di Marzo V; Finazzi-Agrò A
Arch Biochem Biophys; 2001 Sep; 393(2):321-8. PubMed ID: 11556820
[TBL] [Abstract][Full Text] [Related]
31. Effect of lipid rafts on Cb2 receptor signaling and 2-arachidonoyl-glycerol metabolism in human immune cells.
Bari M; Spagnuolo P; Fezza F; Oddi S; Pasquariello N; Finazzi-Agrò A; Maccarrone M
J Immunol; 2006 Oct; 177(8):4971-80. PubMed ID: 17015679
[TBL] [Abstract][Full Text] [Related]
32. FAAH and anandamide: is 2-AG really the odd one out?
Di Marzo V; Maccarrone M
Trends Pharmacol Sci; 2008 May; 29(5):229-33. PubMed ID: 18394720
[TBL] [Abstract][Full Text] [Related]
33. Correlating FAAH and anandamide cellular uptake inhibition using N-alkylcarbamate inhibitors: from ultrapotent to hyperpotent.
Nicolussi S; Chicca A; Rau M; Rihs S; Soeberdt M; Abels C; Gertsch J
Biochem Pharmacol; 2014 Dec; 92(4):669-89. PubMed ID: 25283614
[TBL] [Abstract][Full Text] [Related]
34. Characterization of an anandamide degradation system in prostate epithelial PC-3 cells: synthesis of new transporter inhibitors as tools for this study.
Ruiz-Llorente L; Ortega-Gutiérrez S; Viso A; Sánchez MG; Sánchez AM; Fernández C; Ramos JA; Hillard C; Lasunción MA; López-Rodríguez ML; Díaz-Laviada I
Br J Pharmacol; 2004 Feb; 141(3):457-67. PubMed ID: 14718261
[TBL] [Abstract][Full Text] [Related]
35. Lipidomic metabolism analysis of the endogenous cannabinoid anandamide (N-arachidonylethanolamide).
Placzek EA; Cooper BR; Placzek AT; Chester JA; Davisson VJ; Barker EL
J Pharm Biomed Anal; 2010 Nov; 53(3):567-75. PubMed ID: 20417049
[TBL] [Abstract][Full Text] [Related]
36. Progesterone up-regulates anandamide hydrolase in human lymphocytes: role of cytokines and implications for fertility.
Maccarrone M; Valensise H; Bari M; Lazzarin N; Romanini C; Finazzi-Agrò A
J Immunol; 2001 Jun; 166(12):7183-9. PubMed ID: 11390466
[TBL] [Abstract][Full Text] [Related]
37. The fatty acid amide hydrolase (FAAH).
Deutsch DG; Ueda N; Yamamoto S
Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):201-10. PubMed ID: 12052036
[TBL] [Abstract][Full Text] [Related]
38. Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis--a difficult issue to handle.
Fowler CJ; Tiger G; Ligresti A; López-Rodríguez ML; Di Marzo V
Eur J Pharmacol; 2004 May; 492(1):1-11. PubMed ID: 15145699
[TBL] [Abstract][Full Text] [Related]
39. Anandamide transport: a critical review.
Glaser ST; Kaczocha M; Deutsch DG
Life Sci; 2005 Aug; 77(14):1584-604. PubMed ID: 15979096
[TBL] [Abstract][Full Text] [Related]
40. Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system.
Cravatt BF; Lichtman AH
Curr Opin Chem Biol; 2003 Aug; 7(4):469-75. PubMed ID: 12941421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]